Evidence map›Paper›PMID 37563351›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2023

Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.

Nathaniel Barry, Roslyn J Francis, Martin A Ebert, Eng-Siew Koh, Pejman Rowshanfarzad, Ghulam Mubashar Hassan, Jake Kendrick, Hui K Gan, Sze T Lee, Eddie Lau and 28 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Cancers · 2023
    Review
  7. Boosting the acceptance ofEuropean journal of nuclear medicine and molecular imaging · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors.

Nathaniel BarrySchool of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia. Nathaniel.barry@research.uwa.edu.au.ORCID 0000-0002-9009-5909
Roslyn J FrancisDepartment of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Martin A EbertSchool of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia.
Eng-Siew KohDepartment of Radiation Oncology, Liverpool and Macarthur Cancer Therapy Centres, Liverpool, NSW, Australia.
Pejman RowshanfarzadSchool of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia.
Ghulam Mubashar HassanSchool of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia.
Jake KendrickSchool of Physics, Mathematics and Computing, University of Western Australia, WA, Crawley, Australia.
Hui K GanDepartment of Medical Oncology, Austin Hospital, Melbourne, VIC, Australia.
Sze T LeeOlivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
Eddie LauDepartment of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia.
Bradford A MoffatDepartment of Radiology, University of Melbourne, Melbourne, VIC, Australia.
Greg FittDepartment of Radiology, Austin Health, Melbourne, VIC, Australia.
Alisha MooreTrans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia.
Paul ThomasDepartment of Nuclear Medicine, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
David A PattisonDepartment of Nuclear Medicine, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
Tim AkhurstDepartment of Medicine, University of Melbourne, Melbourne, VIC, Australia.
Ramin AlipourDepartment of Medicine, University of Melbourne, Melbourne, VIC, Australia.
Elizabeth L ThomasDepartment of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Edward HsiaoDepartment of Nuclear Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia.
Geoffrey P SchembriDepartment of Nuclear Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia.
Peter LinSouth Western Sydney Clinical School, UNSW Medicine, University of New South Wales, Liverpool, NSW, Australia.
Tam LyDepartment of Nuclear Medicine, Liverpool Hospital, Liverpool, NSW, Australia.
June YapDepartment of Nuclear Medicine, Liverpool Hospital, Liverpool, NSW, Australia.
Ian KirkwoodDepartment of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.
Wilson VallatDepartment of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.
Shahroz KhanDepartment of Nuclear Medicine, Canberra Hospital, Woden, ACT, Australia.
Dayanethee KrishnaDepartment of Nuclear Medicine, Canberra Hospital, Woden, ACT, Australia.
Stanley NgaiDepartment of Nuclear Medicine, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
Chris YuDepartment of Nuclear Medicine, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
Scott BeuzevilleDepartment of Nuclear Medicine, St George Hospital, Kogarah, NSW, Australia.
Tow C YeowDepartment of Nuclear Medicine, St George Hospital, Kogarah, NSW, Australia.
Dale BaileyDepartment of Nuclear Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia.
Olivia CookTrans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia.
Angela WhiteheadTrans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia.
Rachael DykyjTrans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia.
Alana RossiTrans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia.
Andrew GroseTrans Tasman Radiation Oncology Group (TROG Cancer Research), University of Newcastle, Callaghan, NSW, Australia.
Andrew M ScottOlivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.

Funding

Department of Health and Aged Care, Australian Government MRF1152501Department of Health and Aged Care, Australian Government MRF9500003National Health and Medical Research Council 1177837
6 · The paper itself

Abstract

purposeThe O-(2-[

methodsSites were required to complete contouring and dynamic analysis by ≥ 2 NMPs on benchmarking cases (n = 6) assessing biological tumour volume (BTV) delineation (3 × FET1) and image interpretation (3 × FET3). Data was reviewed by experts and violations noted. BTV definition includes tumour-to-background ratio (TBR) threshold of 1.6 with crescent-shaped background contour in the contralateral normal brain. Recurrence/pseudoprogression interpretation (FET3) required assessment of maximum TBR (TBR

resultsData was accrued from 21 NMPs (10 centres, n ≥ 2 each) and 20 underwent review. The initial pass rate was 93/119 (78.2%) and 27/30 requested resubmissions were completed. Violations were found in 25/72 (34.7%; 13/12 minor/major) of FET1 and 22/74 (29.7%; 14/8 minor/major) of FET3 reports. The primary reasons for resubmission were as follows: BTV over-contour (15/30, 50.0%), background placement (8/30, 26.7%), TAC classification (9/30, 30.0%), and image interpretation (7/30, 23.3%). CoV median and range for BTV, TBR

conclusionThe FIG study credentialing program has increased expertise across study sites. TBR

Indexed as

Brain NeoplasmsFicusGlioblastomaNuclear MedicineAustraliaHumansMagnetic Resonance ImagingPositron-Emission TomographyProspective StudiesTyrosineTyrosineClinical trialsCredentialingFET PETGlioblastomaInter-observer

Identifiers

PMID37563351
PMCPMC10611835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.